Silexon Intelligent Technology Co. Ltd. has synthesized heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.